Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New PDT paper mentioning TLD1433

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jun 20, 2023 12:41pm

203 Views

Post# 35505511

RE:New PDT paper mentioning TLD1433

I hope these researchers take due note of the trial results you sent them.

Sometimes these articles have long lead times which prevent the writers from including the latest research. This happened with an article of Dr. Peter Black a few years ago where TLD1433 barely got a mention. He included more extensive information about TLD1433 in later articles and is now the PI of our UBC clinical study site.

ScienceFirst wrote:
"1433" mentioned twice.

They need to go deeper on the latest TLD1433 results. Their article would have been even more upbeat in their conclusion as they could have clearly mentioned a long-awaited breakthrough. I wrote to these researchers by providing them with the latest mid-Ph. 2 results.

Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

Mafalda Penetra
,
Lus G. Arnaut
&
Lgia C. Gomes-da-Silva

Article: 2226535 | Received 23 May 2023, Accepted 13 Jun 2023, Published online: 18 Jun 2023

https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2226535?src=